CEMI about to bounce
Hello,
What is CEMI?
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
News
(Bloomberg) -- Chembio Diagnostics stock lost more than half its value on Wednesday after U.S. regulators revoked its right to sell a test for Covid-19 antibodies over accuracy concerns.
My Thoughts For You
Yes, we saw this stock plummet regarding the news but the company is not finished and this drop could be a bargain buy for investors which will make this regular flat come to fruition. If we see this meltdown even further towards 105.00%, 123.60% to138.00% fib, this will still be bullish. If the stock goes any lower then these fib levels, then this idea about a flat is void and a new TA will have to be considered.
If you're not sure how to get into a trade or when to take profits then check out this tutorial I have created in the comments section under "My Trade Advice For You"
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
What is CEMI?
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
News
(Bloomberg) -- Chembio Diagnostics stock lost more than half its value on Wednesday after U.S. regulators revoked its right to sell a test for Covid-19 antibodies over accuracy concerns.
My Thoughts For You
Yes, we saw this stock plummet regarding the news but the company is not finished and this drop could be a bargain buy for investors which will make this regular flat come to fruition. If we see this meltdown even further towards 105.00%, 123.60% to138.00% fib, this will still be bullish. If the stock goes any lower then these fib levels, then this idea about a flat is void and a new TA will have to be considered.
If you're not sure how to get into a trade or when to take profits then check out this tutorial I have created in the comments section under "My Trade Advice For You"
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
Publications connexes
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.